Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Impax/Teva Wellbutrin SR Generic Cleared To Launch By Court, FDA

Executive Summary

Impax' bupropion sustained-release generic is cleared for launch following an appeals court ruling that the company does not infringe GlaxoSmithKline's Wellbutrin SR/Zyban patent

You may also be interested in...

Eon Wellbutrin SR Generic Launch Delayed By Two Restraining Orders

Eon's launch of generic bupropion extended-release 100 mg (GlaxoSmithKline's Wellbutrin SR) depends on the resolution of two temporary restraining orders: one from GSK and one from Andrx

Patent Infringement Claims Clarified In Festo Ruling

A federal appeals court decision in the Festo case further clarifies the circumstances under which pharmaceutical patent holders can assert infringement claims under the doctrine of equivalents

Wellbutrin SR Patent Needs Further Review, Appeals Court Agrees With GSK

An appeals court ruling for GlaxoSmithKline in Wellbutrin SR patent litigation against Andrx finds the district court erred in its construction of GSK's patent claims

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts